Returning guest, Dr. William Sandborn, Chief of the Division of Gastroenterology at UC San Diego Health, discusses recent data from the Phase 3 UNIFI study evaluating the safety and efficacy of Janssen's STELARA® (ustekinumab) as a maintenance therapy in patients with moderately to severely active ulcerative colitis who previously failed biologic or conventional therapy. The long-term extension study out to two years, includes an abstract showing the effect of treatment on stool frequency and rectal bleeding. These data were presented at the 2020 American College of Gastroenterology (ACG) Annual Meeting.
#STELARA #Ustekinumab #UlcerativeColitis
Visit our website
www.healtprofessionalradio.com.au
Follow us on our social media channels
Facebook: [ Ссылка ]
Twitter: [ Ссылка ]
Google+: [ Ссылка ]...
Pinterest: [ Ссылка ]...
Linkedin: [ Ссылка ]...
Instagram: [ Ссылка ]...
Subscribe to our podcast channels
Soundcloud: [ Ссылка ]...
Itunes: [ Ссылка ]...
Support us on Patreon
[ Ссылка ]
STELARA® Phase 3 UNIFI Study - Ulcerative Colitis
Теги
health carehealth professionalshealth professional radiohealth radiohealth podcasthealth radio usahealth radio australiahealth radio ukdoctorsnursesmedical technologyhealth care studyhealth care researchhealth care tipshealth care systemhealth care providerhealth care channelpodcastradioSTELARAPhase 3 UNIFI StudyUlcerative ColitisDr. William SandbornUC San Diego HealthAmerican College of Gastroenterology
